The invention relates to substituted enaminones of Formula I and their derivatives and the discovery that these compounds modulate the effect of &gamma-aminobutyric acid (GABA) on the GABAA receptor complex in a therapeutically relevant fashion and may be used to ameliorate CNS disorders amenable to modulation of the GABAA receptor complex.